peptid.fun is a Solana launchpad where every token funds real peptide research. As market cap grows, autonomous AI agents trigger progressively deeper scientific validation — from PubMed pulls to AlphaFold predictions to wet-lab synthesis. Discovery is permissionless. Funding is the curve.
Anyone uploads a peptide hypothesis — sequence, target, mechanism. The bonding curve mints 1B tokens against your thesis. No KYC. No gatekeepers. No diligence committee.
Traders buy the curve. As market cap rises, the protocol unlocks research tiers automatically using treasury fees. No team allocation. Fees are escrowed and released only on milestone trigger.
Autonomous agents execute each tier on-chain. Results pin to Arweave; hashes attest to the token contract. Holders mint Discovery NFTs at every tier graduation. The chain remembers.
●PROTOCOL IS DETERMINISTIC · TRIGGERS ARE ON-CHAIN · HUMAN INTERVENTION IS NOT REQUIRED · NOT MEDICAL ADVICE
Cost is funded entirely from the token's research treasury (1% of trade fees). Triggers are deterministic and verified on-chain. Any holder may invoke the dispatcher once market cap is sustained for ≥ 24 hours.
Exhaustive PubMed + bioRxiv scrape. Claude synthesizes a position paper covering known mechanism, prior art, and adjacent scaffolds. SHA-256 hash attested to the token contract.
BLAST homology search across UniProt + RefSeq. Known target prediction. Multiple sequence alignment + conservation analysis across species. Disorder + flexibility profiling.
ESMFold + AlphaFold structure prediction. Binding pocket analysis. Surface electrostatics. Ramachandran plot. Confidence scored per-residue (pLDDT).
AutoDock Vina molecular docking against predicted target. ADMET prediction. Toxicity flagging via DeepTox. Off-target panel screened against 478-protein liability set.
Real synthesis order via CRO partner (GenScript / Pepscan). HPLC + MS QC. Binding assay returned with chain-of-custody affidavit. Material is held in escrow vault, available for further assays.
Animal model pilot via partner CRO under GLP-equivalent SOPs. 21-day protocol. Full data deposited on-chain with optional opt-in to ecosystem-wide IP rail. IRB out of scope; this is preclinical.
Failed validations are not censored. A negative result is still an attested result. The chain remembers either way.
Tier 05+ involves physical material. Chain-of-custody is enforced by partner CROs and notarized to the contract.
Graduations from Tier 06 enter the open ecosystem rail. IP is optional and never custodial.
“TRADITIONAL PEPTIDE R&D COSTS $50M AND TAKES 8 YEARS. WE'RE COMPRESSING IT TO $50K AND 8 WEEKS. THE COMMUNITY FUNDS, THE AGENT VALIDATES, THE CHAIN REMEMBERS.”
Traditional peptide R&D costs $50M and takes 8 years. The bottleneck is not science — it is capital allocation, IP gating, and academic latency. Promising hypotheses die in inbox threads.
A bonding curve is a real-time prediction market on a peptide thesis. The market cap is not speculation — it is the literal cost of validation. Conviction → capital → assay.
What used to require a graduate student, a PI, and a six-month grant cycle now runs in 20 minutes against open APIs. Agents do not get tired and do not gatekeep.
On-chain attestation means no fraud, no retraction, no quiet failure. Every result — positive, negative, or null — is a permanent contribution to the open peptide commons.
Both, by design. The market cap signals conviction; the protocol converts that conviction into actual experiments — PubMed pulls, AlphaFold runs, then physical synthesis at Tier 05. Every output is hashed on-chain. Speculation funds science. Science either confirms or invalidates the hypothesis.
STILL UNCERTAIN? READ THE DOCS → | JOIN THE LAB CHANNEL ON DISCORD →